Guangzhou Wondfo BiotechLtd Future Growth
Future criteria checks 5/6
Guangzhou Wondfo BiotechLtd is forecast to grow earnings and revenue by 27.5% and 21.1% per annum respectively. EPS is expected to grow by 26.9% per annum. Return on equity is forecast to be 13.9% in 3 years.
Key information
27.5%
Earnings growth rate
26.9%
EPS growth rate
| Medical Equipment earnings growth | 26.5% |
| Revenue growth rate | 21.1% |
| Future return on equity | 13.9% |
| Analyst coverage | Low |
| Last updated | 29 Oct 2024 |
Recent future growth updates
Recent updates
Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture
Nov 18
Guangzhou Wondfo BiotechLtd's (SZSE:300482) Shareholders May Want To Dig Deeper Than Statutory Profit
Nov 01Cautious Investors Not Rewarding Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Performance Completely
Sep 06Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture
Jul 27Guangzhou Wondfo BiotechLtd's (SZSE:300482) Solid Earnings May Rest On Weak Foundations
Apr 29A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price
Mar 27There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital
Feb 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4,775 | 1,013 | N/A | 1,086 | 4 |
| 12/31/2025 | 3,951 | 818 | N/A | 917 | 4 |
| 12/31/2024 | 3,265 | 649 | N/A | 927 | 4 |
| 9/30/2024 | 2,942 | 524 | 107 | 538 | N/A |
| 6/30/2024 | 2,852 | 509 | 230 | 624 | N/A |
| 3/31/2024 | 2,794 | 502 | 289 | 664 | N/A |
| 12/31/2023 | 2,765 | 488 | -104 | 329 | N/A |
| 9/30/2023 | 2,989 | 357 | 116 | 569 | N/A |
| 6/30/2023 | 3,136 | 354 | -56 | 459 | N/A |
| 3/31/2023 | 3,887 | 497 | 1,268 | 1,818 | N/A |
| 1/1/2023 | 5,681 | 1,197 | 1,099 | 1,682 | N/A |
| 9/30/2022 | 5,550 | 1,247 | 905 | 1,472 | N/A |
| 6/30/2022 | 5,538 | 1,257 | 898 | 1,461 | N/A |
| 3/31/2022 | 5,290 | 1,383 | -270 | 287 | N/A |
| 12/31/2021 | 3,361 | 634 | 208 | 665 | N/A |
| 9/30/2021 | 3,145 | 695 | 18 | 621 | N/A |
| 6/30/2021 | 3,060 | 741 | -1 | 557 | N/A |
| 3/31/2021 | 2,956 | 692 | 113 | 594 | N/A |
| 12/31/2020 | 2,811 | 634 | 642 | 1,062 | N/A |
| 9/30/2020 | 2,821 | 663 | 657 | 886 | N/A |
| 6/30/2020 | 2,711 | 630 | 885 | 1,053 | N/A |
| 3/31/2020 | 2,172 | 413 | 595 | 775 | N/A |
| 12/31/2019 | 2,072 | 387 | 131 | 310 | N/A |
| 9/30/2019 | 1,921 | 375 | 175 | 329 | N/A |
| 6/30/2019 | 1,817 | 352 | 137 | 296 | N/A |
| 3/31/2019 | 1,748 | 325 | 97 | 232 | N/A |
| 12/31/2018 | 1,650 | 308 | 117 | 248 | N/A |
| 9/30/2018 | 1,542 | 280 | 69 | 198 | N/A |
| 6/30/2018 | 1,498 | 264 | N/A | 175 | N/A |
| 3/31/2018 | 1,323 | 231 | N/A | 186 | N/A |
| 12/31/2017 | 1,145 | 211 | N/A | 169 | N/A |
| 9/30/2017 | 921 | 181 | N/A | 51 | N/A |
| 6/30/2017 | 747 | 174 | N/A | 100 | N/A |
| 3/31/2017 | 624 | 154 | N/A | 116 | N/A |
| 12/31/2016 | 547 | 145 | N/A | 112 | N/A |
| 9/30/2016 | 525 | 158 | N/A | 143 | N/A |
| 6/30/2016 | 486 | 147 | N/A | 141 | N/A |
| 3/31/2016 | 450 | 131 | N/A | 145 | N/A |
| 12/31/2015 | 429 | 125 | N/A | 132 | N/A |
| 9/30/2015 | 382 | 106 | N/A | 108 | N/A |
| 6/30/2015 | 380 | 105 | N/A | 99 | N/A |
| 3/31/2015 | 365 | 96 | N/A | 107 | N/A |
| 12/31/2014 | 365 | 98 | N/A | 104 | N/A |
| 12/31/2013 | 248 | 59 | N/A | 101 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300482's forecast earnings growth (27.5% per year) is above the savings rate (2.8%).
Earnings vs Market: 300482's earnings (27.5% per year) are forecast to grow faster than the CN market (26.2% per year).
High Growth Earnings: 300482's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300482's revenue (21.1% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 300482's revenue (21.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300482's Return on Equity is forecast to be low in 3 years time (13.9%).